Spero Pharma (SPRO) Net Margin

Graphic logo of sperotherapeutics.com (SPRO)

Spero Therapeutics develops advanced antibiotics for hospitals, focusing on the therapy of severe pulmonary and urinary tract infections. Revenue is based on licensing fees and the sale of drugs targeting resistant bacteria. This net profit margin chart provided in GURU.Markets helps identify efficiency trends, where the -73.90 indicator shows the latest value. Independence from macroeconomic factors makes the asset a reliable defensive tool.

Spero Therapeutics (SPRO) Company Sales Margin: for the period 07/04/2022 - 11/19/2026

Analytical breakdowns for Spero (SPRO)

- market value and analyst target forecast:
Comprehensive company analysis:Spero Therapeutics
Manufactured product of Spero Therapeutics Inc

Sales margins determine the share of net profit in every dollar of revenue, reflecting overall operational efficiency. An increase in this ratio signals business scalability, although a high share price may offset the benefit. By analyzing the company's commercial profit margin, an investor assesses the speed of asset monetization. For Spero Therapeutics (SPRO), this metric is critical due to the colossal costs of clinical trials. Strict FDA oversight and patent protection create high profitability volatility.